Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) EBITDA (2022 - 2025)

Axsome Therapeutics' EBITDA history spans 4 years, with the latest figure at -$27.0 million for Q4 2025.

  • For Q4 2025, EBITDA rose 62.88% year-over-year to -$27.0 million; the TTM value through Dec 2025 reached -$166.8 million, up 40.56%, while the annual FY2025 figure was -$166.8 million, 40.56% up from the prior year.
  • EBITDA for Q4 2025 was -$27.0 million at Axsome Therapeutics, up from -$46.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$6.4 million in Q1 2023 and bottomed at -$98.3 million in Q4 2023.
  • The 4-year median for EBITDA is -$58.4 million (2022), against an average of -$53.7 million.
  • The largest annual shift saw EBITDA skyrocketed 83.35% in 2023 before it crashed 955.46% in 2024.
  • A 4-year view of EBITDA shows it stood at -$59.9 million in 2022, then crashed by 64.02% to -$98.3 million in 2023, then rose by 26.11% to -$72.6 million in 2024, then surged by 62.88% to -$27.0 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's EBITDA are -$27.0 million (Q4 2025), -$46.1 million (Q3 2025), and -$36.7 million (Q2 2025).